key: cord-0990230-10hp02fp
authors: Stokes, Claire L.; Patel, Pratik A.; Sabnis, Himalee S.; Mitchell, Sarah G.; Yildirim, Inci B.; Pauly, Melinda G.
title: Severe COVID‐19 disease in two pediatric oncology patients
date: 2020-07-06
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.28432
sha: 5bed120922cb18980ed7ed487b1a09d5240202c4
doc_id: 990230
cord_uid: 10hp02fp

nan

her corrected QT interval from 416 to 440 was noted on daily electrocardiogram while on hydroxychloroquine, but she did not experience any arrythmias.

Additionally, rising IL-6 levels (15 pg/mL) and impending respiratory failure prompted use of tocilizumab (800 mg daily on HD 7 and 8). 11, 12 Her fever curve and C-reactive protein subsequently improved, but she remained febrile and required high levels of oxygen support until initiation of remdesivir ( Figure 2A) . She was weaned to room air and transferred out of the ICU on HD 14.

A Caucasian 16-year-old male with BMI of 29 kg/m 2 presented acutely with fever and gingival bleeding 19 months following comple- F I G U R E 2 A, Trends of ferritin (green), maximum daily temperature (red), C-reactive protein (blue), and supplemental oxygen (black) of patient 1. Hydroxychloroquine was started on hospital day 6 (HD 6), tocilizumab was given on HD 7 and 8, and remdesivir was started on HD 10. Patient 1 ICU course was from HD 7 to HD 14 (red bar). B, Trends of ferritin (green), maximum daily temperature (red), C-reactive protein (blue), and supplemental oxygen (black) of patient 2. Hydroxychloroquine was started on HD 3 and remdesivir was started on HD 4. Patient 2 ICU course was from HD 0 to HD 10 (red bar). T max , maximum daily temperature in degrees Celsius; CRP, C-reactive protein; HCQ, hydroxychloroquine; TCZ, tocilizumab; RDV, remdesivir While Georgia only represents approximately 2.5% of nationwide COVID-19 cases, 13,14 we have seen multiple cases of severe COVID-19. The Aflac Cancer and Blood Disorders Center is a large pediatric oncology practice with over 450 newly diagnosed patients annually.

In contrast with published reports, 4 the pediatric cancer patients with COVID-19 described here exhibited severe respiratory distress and significant hyperinflammation requiring intensive care.

Early evidence from China points to older age and underlying medical conditions as risk factors for severe COVID-19. 15 Obesity, an established risk factor for severe disease in influenza patients, 16 also carries an increased risk of hospitalization for COVID-19. 17 In an analysis of patients under age 60 years, obese patients were 1.8 and 3.6 times more likely to require intensive care for COVID-19

with BMI 30-34 kg/m 2 or ≥35 kg/m 2 , respectively. 18 Our patients'

CDC COVID-19 Response Team. Coronavirus disease 2019 in children -United States

COVID-19 in children: initial characterization of the pediatric disease

Detection of COVID-19 in children in early

SARS-CoV-2 infection in children

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer

Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hematooncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplant

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Effective treatment of severe COVID-19 patients with tocilizumab

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic

Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 states

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Compassionate use of remdesivir for patients with severe COVID-19

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Tocilizumab treatment in COVID-19: a single center experience

Challenges posed by COVID-19 to children with cancer

Oncology practice during the COVID-19 pandemic

Presumed asymptomatic carrier transmission of COVID-19

A systematic review of dysgeusia induced by cancer therapies